TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06735014

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Participants will undergo 3T MRI scanning of the brain and cervical spine MRIs

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma neurofilament light chain (NfL) quantification
Description: Participants will undergo a blood draw for the quantification of plasma neurofilament light chain

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma neurofilament light chain (NfL) quantification
Description: Participants will undergo a blood draw for the quantification of plasma neurofilament light chain
Study: NCT06734208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered as a single oral dose as specified for the respective cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered as a single oral dose as specified for the respective cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered as a single oral dose as specified for the respective cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered as a single oral dose as specified for the respective cohort.
Study: NCT06745557

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: denovoSkin(TM)
Description: Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: denovoSkin(TM)
Description: Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area

Intervention type: OTHER
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin to the control area

Intervention type: OTHER
Group type: OTHER
Intervention: STSG
Description: Transplantation of autologous split-thickness skin to the control area
Study: NCT06744647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2030
Description: ALXN2030 will be administered subcutaneously (SC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2030
Description: ALXN2030 will be administered subcutaneously (SC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered SC.
Study: NCT06736769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Description: Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.
Study: NCT06742697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility, Resistance, Aerobic, Movement Execution training
Description: Flexibility: static and dynamic stretching combined with sensory, high-frequency electrical stimulation to reduce spasticity and improve mobility.~Resistance training: core stability and lower limb strength training in conditions of instability, to improve strength, coordination, and balance.~Movement execution training: gait training according to motor learning principles.~Aerobic exercise: in the form of high-intensity interval training at the end of each session, to improve cardiovascular status and foster motor learning consolidation (probably due to the release of brain derived neurothrophic factors).
Study: NCT06479824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty)
Description: In TRAIPTA, catheter tools cross the wall of the heart to enter the pericardial space surrounding the heart, encircle the heart around the atrioventricular groove, and apply tension to reshape and narrow the heart to help the leaky tricuspid valve to function better. After placing the belt, a closure device is deployed to close the puncture in the right atrial appendage.
Study: NCT06745323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab will be administered by IV infusion.
Study: NCT06357091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with Shark Screw ACL®
Description: ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction with biocomposite screw (Mecta)
Description: ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
Study: NCT06072300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity calorie equivalent labelling
Description: Physical activity calorie equivalent labelling on beverage vending machines
Study: NCT06301828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab Injection
Description: Endostar+SBRT+Envafolimab Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar+SBRT+Envafolimab Injection
Study: NCT05555797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 308nm Excimer laser
Description: Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Topical Gel
Description: Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Valerate
Description: .Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
Study: NCT05751590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comined use of gliddescope and fiberoptic broncscopy
Description: endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronscopy
Description: endotrachotreal intubation will be done by Fiberoptic broncscopy
Study: NCT06399432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: In the Mediterranean Diet, all foods are included. Red meat will be limited to 1/week, poultry to ≤3 times/week and fish to 2-3 times/week. Supplementation with extra-virgin olive oil and nuts, providing 1 liter of olive oil per week and 30 gr a day of nuts.~The dietician will personalize the dietary advice by adapting it to the patient's condition, preferences and beliefs, will encourage adherence, and transmit a sense of empowerment. A change in diet with specific, attainable goals will be negotiated between the dietician and the participant.~Dieticians will conduct a phone call once in every 2-week period to assess dietary compliance using a 24-hour food recall, the Mediterranean Diet Adherence Form. MD patients will keep a diet diary for 3 days every two weeks, which they will discuss with the dietician during their scheduled dietician assessment. The Baseline Visit with the dietician can occur either in-person or via video communication software.
Study: NCT06743685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALthy Beginnings
Description: HEALthy Beginnings, an innovative, enhanced, trauma-informed, chronic disease self-care program and nurse-driven intervention, developed and tailored for middle-aged, and older, homeless women (MAO-HW).
Study: NCT05681156

Intervention type: OTHER
Intervention: N/A- There is no intervention.
Description: There is no intervention.
Study: NCT06747793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The intervention will consist of relaxing virtual reality stimulation, which will be started after obtaining informed consent. Immersive 360-degree videos (nature environments) will be played inside a head-mounted display, with the video sound played inside headphones. Each virtual reality video will last 30 minutes. The stimulation will be provided two times per day, morning and evening, every day until the patient ICU discharge, or the maximum of 7 days will be reached. The intervention group will also receive standard intensive care unit care, same as in the control group.
Study: NCT06751446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scenario-based Simulation Skill Training
Description: Scenario-based simulation is an educational approach that immerses students in realistic clinical scenarios, allowing them to practice decision-making and problem-solving in a safe, controlled environment. It challenges students to assess patient data, identify priorities, and implement interventions. Through guided debriefing sessions, students reflect on their actions, justify their decisions, and explore alternative strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Skill Training
Description: Traditional skill training in nursing education focuses on developing core technical skills through direct instruction, demonstrations, and hands-on practice. It emphasises mastery of essential tasks and conducting patient assessments. Students follow standardized protocols and procedures to ensure patient safety and accuracy in their practice
Study: NCT04913181

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence sepsis prediction model
Description: The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence sepsis prediction model
Description: The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
Study: NCT06743347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Contrast
Description: Pass a Phase Contrast MRI. No injection required.
Study: NCT06750185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL1
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL2
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL3
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL4
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL5 (intermediate)
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL6 (intermediate)
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT317 DL7 (additional)
Description: Intravenous infusion
Study: NCT05810038

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimegepant
Description: Rimegepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: Rimegepant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT06746428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Coaching
Description: An exercise coaching program tailored for women with Stage I-IVA endometrial cancer who have undergone total or modified radical hysterectomy with surgical staging. The intervention targets a total of 8 participants who are planned to complete pelvic external beam radiation therapy as part of their adjuvant treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Coaching
Description: An exercise coaching program tailored for women with Stage I-IVA endometrial cancer who have undergone total or modified radical hysterectomy with surgical staging. The intervention targets a total of 8 participants who are planned to complete pelvic external beam radiation therapy as part of their adjuvant treatment.
Study: NCT06757036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: the group where Laughter Yoga is performed
Study: NCT06749587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL RHA® 1
Description: Product injection in infraorbital hollows~TEOSYAL RHA® 1 is a sterile, transparent, non-pyrogenic, viscoelastic gel made of Hyaluronic Acid (HA) of non-animal origin
Study: NCT06752109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antipronation Taping
Description: Before applying the tape, its length was measured by passing it over the areas on the foot where it would be applied. The tape was first attached to the medial side of the big toe, with tension in the direction of flexion and abduction of the toe. The ankle was then positioned in full plantar flexion. The tape was applied from the medial side of the foot towards the heel, wrapping around it, and then directed towards the sole. While the foot was in an inversion position at the navicular level, the tape was applied with maximum tension from medial to lateral and brought back to the sole. The remainder of the tape, with maximum tension, was applied from the sole to the dorsal side of the ankle, ending without tension at the proximal and lateral side of the leg. A second strip of tape, with maximum tension, was applied to support the medial longitudinal arch. The ends of the tape were placed over the malleoli without tension, aiming to reduce excessive pronation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: In the sham taping application, the length of the tape was measured by passing it over the areas where it would be applied. The tape was applied to the medial side of the big toe, but without tension, simply placed. Then, the tape was directed towards the sole of the foot, passing over the heel. At the navicular level, the tape was applied from medial to lateral, returning to the sole without tension. A second strip of tape was applied to the sole without tension. The ends of the tape were placed over the malleoli without stretching. Since no tension was applied, this application was only placed and has a limited effect on reducing excessive pronation.
Study: NCT06736132

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal oxygen
Description: In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: In this study, we will use high-flow nasal oxygen for preoxygenation in patients undergoing elective anaesthesia. Preoxygenation with high-flow nasal oxygen is most often performed at flow rates of \<50 l/min. In this study, patients will be randomised to preoxygenation using high-flow nasal oxygen and flow rates of 45 l/min, 70 l/min or 95 /min.
Study: NCT04983485

Intervention type: OTHER
Intervention: Observational
Description: Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
Study: NCT06754917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-Forward-Web
Description: This is a self-administered web-based mind-body intervention that consists of 5 30-minute video sessions disseminating tailored relaxation, mindfulness, and cognitive-behavioral skills for COP. Ultimately, the Face-Forward-Web program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive coping behaviors.
Study: NCT04183595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (N1, N3-bis(2- mercaptoethyl)isophthalamide)
Description: 600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Excipients microcrystalline cellulose, silica and magnesium stearate
Description: 6 Capsules will be administered every 24 hours for 14 days.
Study: NCT04972708

Intervention type: GENETIC
Intervention: Cross-sectional genetics study
Description: Cross-sectional genetics study
Study: NCT06753500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autonomic neural blockade
Description: Autonomic nerve block performed with:~* Bupivacaine: 20 mL of 0.5%.~* Dexamethasone: 8 mg.
Study: NCT04804657

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sage extracts Cognivia
Description: Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
Study: NCT04885322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
Study: NCT06094218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Description: BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Behavioral health treatment as it is typically provided at the treatment site.
Study: NCT06434766

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: sham theta-burst transcranial magnetic stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta-burst stimulation (iTBS)
Description: intermittent theta-burst transcranial magnetic stimulation
Study: NCT06193408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR-AD-1005
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study: NCT04765644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Two 200 mg capsules per day (400 mg/day) for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules/day for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine + placebo
Description: L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine + celecoxib
Description: L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
Study: NCT06038084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronpass Tab.
Description: Twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Erdos capsule
Description: Three times a day (It is for the masking.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erdos capsule
Description: Three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Bronpass Tab.
Description: Twice a day (It is for the masking.)
Study: NCT05803057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS stimulation treatment
Description: Using the TMS treatment coli to stimulation with high frequency

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS stimulation sham-treatment
Description: Using the TMS sham-treatment coli to stimulation with high frequency